Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 25, 2025
Daily News
June 25, 2025
- Japan Pharma Market to Reach 12.28 Trillion Yen by FY2029: IQVIA
June 25, 2025
- Novartis Taps Cancer Institute Hospital as Priority Trial Site in Japan
June 25, 2025
- MHLW Orders Label Revisions for Desmopressin, Thiamazole
June 25, 2025
- FDA Approves Daiichi’s Datroway for EGFR Lung Cancer
June 25, 2025
- Japan Approves MSD’s Airwin/Welireg, J&J Bispecific, and More
June 25, 2025
- Medipal/JCR’s MPS IIIB Therapy Earns Orphan Status in Europe
June 25, 2025
- JPWA Poll Finds Progress in Unit Price-Based Negotiations, but Frequent and Lengthy Bargaining Persists
June 25, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…